210 related articles for article (PubMed ID: 30925852)
1. Molecular insights into cancer drug resistance from a proteomics perspective.
An Y; Zhou L; Huang Z; Nice EC; Zhang H; Huang C
Expert Rev Proteomics; 2019 May; 16(5):413-429. PubMed ID: 30925852
[TBL] [Abstract][Full Text] [Related]
2. Proteomic characterization of post-translational modifications in drug discovery.
Zhai LH; Chen KF; Hao BB; Tan MJ
Acta Pharmacol Sin; 2022 Dec; 43(12):3112-3129. PubMed ID: 36372853
[TBL] [Abstract][Full Text] [Related]
3. A proteome-level view of brain tumors for a better understanding of novel diagnosis, prognosis, and therapy.
Pai MGJ; Biswas D; Verma A; Srivastava S
Expert Rev Proteomics; 2023; 20(12):381-395. PubMed ID: 37970632
[TBL] [Abstract][Full Text] [Related]
4. Mass spectrometry-assisted gel-based proteomics in cancer biomarker discovery: approaches and application.
Huang R; Chen Z; He L; He N; Xi Z; Li Z; Deng Y; Zeng X
Theranostics; 2017; 7(14):3559-3572. PubMed ID: 28912895
[TBL] [Abstract][Full Text] [Related]
5. Protein post-translational modifications: A key factor in colorectal cancer resistance mechanisms.
Bi B; Qiu M; Liu P; Wang Q; Wen Y; Li Y; Li B; Li Y; He Y; Zhao J
Biochim Biophys Acta Gene Regul Mech; 2023 Dec; 1866(4):194977. PubMed ID: 37625568
[TBL] [Abstract][Full Text] [Related]
6. Proteomics for cancer drug design.
Haymond A; Davis JB; Espina V
Expert Rev Proteomics; 2019 Aug; 16(8):647-664. PubMed ID: 31353977
[No Abstract] [Full Text] [Related]
7. Proteomic insights into paediatric cancer: Unravelling molecular signatures and therapeutic opportunities.
Padhye BD; Nawaz U; Hains PG; Reddel RR; Robinson PJ; Zhong Q; Poulos RC
Pediatr Blood Cancer; 2024 Jun; 71(6):e30980. PubMed ID: 38556739
[TBL] [Abstract][Full Text] [Related]
8. Biomarker Identification through Proteomics in Colorectal Cancer.
Martín-García D; García-Aranda M; Redondo M
Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396959
[TBL] [Abstract][Full Text] [Related]
9. Mass Spectrometry-Based Proteomics: Analyses Related to Drug-Resistance and Disease Biomarkers.
Agostini M; Traldi P; Hamdan M
Medicina (Kaunas); 2023 Sep; 59(10):. PubMed ID: 37893440
[TBL] [Abstract][Full Text] [Related]
10. The potential of optical proteomic technologies to individualize prognosis and guide rational treatment for cancer patients.
Kelleher MT; Fruhwirth G; Patel G; Ofo E; Festy F; Barber PR; Ameer-Beg SM; Vojnovic B; Gillett C; Coolen A; Kéri G; Ellis PA; Ng T
Target Oncol; 2009 Sep; 4(3):235-52. PubMed ID: 19756916
[TBL] [Abstract][Full Text] [Related]
11. Proteomics and biomarkers in clinical trials for drug development.
Lee JM; Han JJ; Altwerger G; Kohn EC
J Proteomics; 2011 Nov; 74(12):2632-41. PubMed ID: 21570499
[TBL] [Abstract][Full Text] [Related]
12. Phosphoproteomics in translational research: a sarcoma perspective.
Noujaim J; Payne LS; Judson I; Jones RL; Huang PH
Ann Oncol; 2016 May; 27(5):787-94. PubMed ID: 26802162
[TBL] [Abstract][Full Text] [Related]
13. Understanding Drug Sensitivity and Tackling Resistance in Cancer.
Tyner JW; Haderk F; Kumaraswamy A; Baughn LB; Van Ness B; Liu S; Marathe H; Alumkal JJ; Bivona TG; Chan KS; Druker BJ; Hutson AD; Nelson PS; Sawyers CL; Willey CD
Cancer Res; 2022 Apr; 82(8):1448-1460. PubMed ID: 35195258
[TBL] [Abstract][Full Text] [Related]
14. Recent advances in mass spectrometry based clinical proteomics: applications to cancer research.
Macklin A; Khan S; Kislinger T
Clin Proteomics; 2020; 17():17. PubMed ID: 32489335
[TBL] [Abstract][Full Text] [Related]
15. Mass Spectrometry Imaging of Fibroblasts: Promise and Challenge.
Angel PM; Rujchanarong D; Pippin S; Spruill L; Drake R
Expert Rev Proteomics; 2021 Jun; 18(6):423-436. PubMed ID: 34129411
[TBL] [Abstract][Full Text] [Related]
16. Proteolytic signaling in cancer.
Salardani M; Barcick U; Zelanis A
Expert Rev Proteomics; 2023; 20(12):345-355. PubMed ID: 37873978
[TBL] [Abstract][Full Text] [Related]
17. Proteomics: a powerful tool to study plant responses to biotic stress.
Liu Y; Lu S; Liu K; Wang S; Huang L; Guo L
Plant Methods; 2019; 15():135. PubMed ID: 31832077
[TBL] [Abstract][Full Text] [Related]
18. The path to clinical proteomics research: integration of proteomics, genomics, clinical laboratory and regulatory science.
Boja ES; Rodriguez H
Korean J Lab Med; 2011 Apr; 31(2):61-71. PubMed ID: 21474978
[TBL] [Abstract][Full Text] [Related]
19. Integration of proteomics in the molecular tumor board.
Thiery J; Fahrner M
Proteomics; 2024 Jun; 24(12-13):e2300002. PubMed ID: 38143279
[TBL] [Abstract][Full Text] [Related]
20. Oncogenic Proteomics Approaches for Translational Research and HIV-Associated Malignancy Mechanisms.
Alvarez-Rivera E; Ortiz-Hernández EJ; Lugo E; Lozada-Reyes LM; Boukli NM
Proteomes; 2023 Jul; 11(3):. PubMed ID: 37489388
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
